Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Progyny (PGNY)

Progyny Q2 revenue up 5.3% to $350.5 million; net income rises to $28.1 million

Positive Impact 3 of 5 earnings Written later

Progyny reported second-quarter 2026 revenue of $350.5 million, up 5.3% from $332.9 million, and net income of $28.1 million, or $0.34 per diluted share, versus $0.19 a year earlier. The company also issued third-quarter and full-year 2026 guidance and said it has repurchased 2 million shares under its May 2026 program, with about $142.5 million remaining under that authorization.

Key points

  • Revenue was $350.5 million, up 5.3%; fertility benefit services revenue rose 7.6% to $230.2 million.
  • Diluted EPS was $0.34 versus $0.19; adjusted EPS was $0.55 versus $0.48.
  • Q3 2026 revenue is projected at $335.0 million to $345.0 million; full-year 2026 revenue at $1.360 billion to $1.385 billion.
  • Operating cash flow was $50.4 million versus $55.5 million a year earlier; the company had no debt as of June 30, 2026.

The filing

CompanyProgyny (PGNY)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:10 PM ET
Accession number0001551306-26-000135

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.